Episode
#525: Multi-Cancer Early Detection Testing
- Published
- May 18, 2026
- Duration seconds
- 2762
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8904567
Actions
POST https://stenobird.com/v1/public/podcasts/the-curbsiders-internal-medicine-podcast-743220/episodes/525-multi-cancer-early-detection-testing/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-curbsiders-internal-medicine-podcast-743220/525-multi-cancer-early-detection-testing.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero , UCSF Cancer Early Detection and Interception , to discuss whether these tests are truly ready for clinical prime time. Claim CME for this episode at curbsiders.vcuhealth.org ! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction 01:57 Current Cancer Screening Programs 06:05 Emerging Blood-Based Cancer Tests 11:55 Test Characteristics and Limitations 18:05 Practical Considerations for Patients 25:33 Direct-to-Consumer Testing/Whole Body MRIs 36:46 Navigating Positive Test Results 45:10 Anxiety and Patient Education 47:08 Future Directions in Cancer Screening Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Margaret Tempero, MD Disclosures Dr. Tempero reports the following financial relationships: Grail (research support), Global Bio Access Fund (Advisor), Bristol Myers Squibb (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Astra Zeneca (Membership on Advisory Committees or Review Panels, Board Membership, etc), Immunovia (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Merck (advisory committee), Renovo Rx (advisory committee), Urogen (Advisor). Financial relationships have not ended. The Curbsiders report no relevant financial disclosures. Sponsor: FIGS Cu…